CAMP vs IONS
CAMP: CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapies to upregulate gene expression and restore protein levels for patients with genetic diseases. IONS: Ionis Pharmaceuticals is a pioneer in RNA-targeted therapies, transitioning into a commercial-stage biotech with a pipeline focused on neurology and cardiometabolic diseases.
Side-by-side fundamentals
| Metric | CAMP | IONS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.70 | $43.30 | |
| Market cap | $232M | $7.2B | |
| Net margin FY2025, SEC XBRL | -2298.5% | -40.4% | IONS higher |
| Operating margin FY2025, SEC XBRL | -1502.4% | -40.4% | IONS higher |
| ROE FY2025, SEC XBRL | -168.5% | -78.0% | IONS higher |
| ROA FY2025, SEC XBRL | -68.2% | -10.8% | IONS higher |
| Debt / equity as of 2026-09-03 | 0.00 | 4.35 | CAMP lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.6% | -7.5% | CAMP higher |
| Revenue CAGR (3y) SEC XBRL | +216.1% | +17.1% | CAMP higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.48 | 0.70 | |
| 1-year return as of 2026-10-08 close | +4.5% | -38.1% | CAMP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.